The national cancer screening program for breast cancer in the Republic of Korea

Is it cost-effective?

Moon Hae Kang, Euncheol Park, Kui Son Choi, Mi Na Suh, Jae Kwan Jun, Eun Cho

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

This goal of this research was to evaluate the cost-effectiveness of the National Cancer Screening Program (NCSP) for breast cancer in the Republic of Korea from a government expenditure perspective. In 2002-2003 (baseline), a total of 8,724,860 women aged 40 years or over were invited to attend breast cancer screening by the NCSP. Those who attended were identified using the NCSP database, and women were divided into two groups, women who attended screening at baseline (screened group) and those who did not (non-screened group). Breast cancer diagnosis in both groups at baseline, and during 5-yearfollow-up was identified using the Korean Central Cancer Registry. The effectiveness of the NCSP for breast cancer was estimated by comparing 5-year survival and life years saved (LYS) between the screened and the unscreened groups, measured using mortality data from the Korean National Health Insurance Corporation and the National Health Statistical Office. Direct screening costs, indirect screening costs, and productivity costs were considered in different combinations in the model. When all three of these costs were considered together, the incremental cost to save one life year of a breast cancer patient was 42,305,000 Korean Won (KW) (1 USD=1,088 KW) for the screened group compared to the non-screened group. In sensitivity analyses, reducing the false-positive rate of the screening program by half was the most cost-effective (incrementalcost-effectiveness ratio, ICER=30,110,852 KW/LYS) strategy. When the upper age limit for screening was set at 70 years, itbecame more cost-effective (ICER=39,641,823 KW/LYS) than when no upper age limit was set. The NCSP for breast cancer in Korea seems to be accepted as cost-effective as ICER estimates were around the Gross Domestic Product. However, cost-effectiveness could be further improved by increasing the sensitivity of breast cancer screening and by setting appropriate age limits.

Original languageEnglish
Pages (from-to)2059-2065
Number of pages7
JournalAsian Pacific Journal of Cancer Prevention
Volume14
Issue number3
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Republic of Korea
Early Detection of Cancer
Breast Neoplasms
Costs and Cost Analysis
Cost-Benefit Analysis
Gross Domestic Product
National Health Programs
Korea
Health Expenditures
Registries
Databases
Survival
Mortality
Health

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

Kang, Moon Hae ; Park, Euncheol ; Choi, Kui Son ; Suh, Mi Na ; Jun, Jae Kwan ; Cho, Eun. / The national cancer screening program for breast cancer in the Republic of Korea : Is it cost-effective?. In: Asian Pacific Journal of Cancer Prevention. 2013 ; Vol. 14, No. 3. pp. 2059-2065.
@article{8e7fe65355b44ff0889adec173f28192,
title = "The national cancer screening program for breast cancer in the Republic of Korea: Is it cost-effective?",
abstract = "This goal of this research was to evaluate the cost-effectiveness of the National Cancer Screening Program (NCSP) for breast cancer in the Republic of Korea from a government expenditure perspective. In 2002-2003 (baseline), a total of 8,724,860 women aged 40 years or over were invited to attend breast cancer screening by the NCSP. Those who attended were identified using the NCSP database, and women were divided into two groups, women who attended screening at baseline (screened group) and those who did not (non-screened group). Breast cancer diagnosis in both groups at baseline, and during 5-yearfollow-up was identified using the Korean Central Cancer Registry. The effectiveness of the NCSP for breast cancer was estimated by comparing 5-year survival and life years saved (LYS) between the screened and the unscreened groups, measured using mortality data from the Korean National Health Insurance Corporation and the National Health Statistical Office. Direct screening costs, indirect screening costs, and productivity costs were considered in different combinations in the model. When all three of these costs were considered together, the incremental cost to save one life year of a breast cancer patient was 42,305,000 Korean Won (KW) (1 USD=1,088 KW) for the screened group compared to the non-screened group. In sensitivity analyses, reducing the false-positive rate of the screening program by half was the most cost-effective (incrementalcost-effectiveness ratio, ICER=30,110,852 KW/LYS) strategy. When the upper age limit for screening was set at 70 years, itbecame more cost-effective (ICER=39,641,823 KW/LYS) than when no upper age limit was set. The NCSP for breast cancer in Korea seems to be accepted as cost-effective as ICER estimates were around the Gross Domestic Product. However, cost-effectiveness could be further improved by increasing the sensitivity of breast cancer screening and by setting appropriate age limits.",
author = "Kang, {Moon Hae} and Euncheol Park and Choi, {Kui Son} and Suh, {Mi Na} and Jun, {Jae Kwan} and Eun Cho",
year = "2013",
month = "1",
day = "1",
doi = "10.7314/APJCP.2013.14.3.2059",
language = "English",
volume = "14",
pages = "2059--2065",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "3",

}

The national cancer screening program for breast cancer in the Republic of Korea : Is it cost-effective? / Kang, Moon Hae; Park, Euncheol; Choi, Kui Son; Suh, Mi Na; Jun, Jae Kwan; Cho, Eun.

In: Asian Pacific Journal of Cancer Prevention, Vol. 14, No. 3, 01.01.2013, p. 2059-2065.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The national cancer screening program for breast cancer in the Republic of Korea

T2 - Is it cost-effective?

AU - Kang, Moon Hae

AU - Park, Euncheol

AU - Choi, Kui Son

AU - Suh, Mi Na

AU - Jun, Jae Kwan

AU - Cho, Eun

PY - 2013/1/1

Y1 - 2013/1/1

N2 - This goal of this research was to evaluate the cost-effectiveness of the National Cancer Screening Program (NCSP) for breast cancer in the Republic of Korea from a government expenditure perspective. In 2002-2003 (baseline), a total of 8,724,860 women aged 40 years or over were invited to attend breast cancer screening by the NCSP. Those who attended were identified using the NCSP database, and women were divided into two groups, women who attended screening at baseline (screened group) and those who did not (non-screened group). Breast cancer diagnosis in both groups at baseline, and during 5-yearfollow-up was identified using the Korean Central Cancer Registry. The effectiveness of the NCSP for breast cancer was estimated by comparing 5-year survival and life years saved (LYS) between the screened and the unscreened groups, measured using mortality data from the Korean National Health Insurance Corporation and the National Health Statistical Office. Direct screening costs, indirect screening costs, and productivity costs were considered in different combinations in the model. When all three of these costs were considered together, the incremental cost to save one life year of a breast cancer patient was 42,305,000 Korean Won (KW) (1 USD=1,088 KW) for the screened group compared to the non-screened group. In sensitivity analyses, reducing the false-positive rate of the screening program by half was the most cost-effective (incrementalcost-effectiveness ratio, ICER=30,110,852 KW/LYS) strategy. When the upper age limit for screening was set at 70 years, itbecame more cost-effective (ICER=39,641,823 KW/LYS) than when no upper age limit was set. The NCSP for breast cancer in Korea seems to be accepted as cost-effective as ICER estimates were around the Gross Domestic Product. However, cost-effectiveness could be further improved by increasing the sensitivity of breast cancer screening and by setting appropriate age limits.

AB - This goal of this research was to evaluate the cost-effectiveness of the National Cancer Screening Program (NCSP) for breast cancer in the Republic of Korea from a government expenditure perspective. In 2002-2003 (baseline), a total of 8,724,860 women aged 40 years or over were invited to attend breast cancer screening by the NCSP. Those who attended were identified using the NCSP database, and women were divided into two groups, women who attended screening at baseline (screened group) and those who did not (non-screened group). Breast cancer diagnosis in both groups at baseline, and during 5-yearfollow-up was identified using the Korean Central Cancer Registry. The effectiveness of the NCSP for breast cancer was estimated by comparing 5-year survival and life years saved (LYS) between the screened and the unscreened groups, measured using mortality data from the Korean National Health Insurance Corporation and the National Health Statistical Office. Direct screening costs, indirect screening costs, and productivity costs were considered in different combinations in the model. When all three of these costs were considered together, the incremental cost to save one life year of a breast cancer patient was 42,305,000 Korean Won (KW) (1 USD=1,088 KW) for the screened group compared to the non-screened group. In sensitivity analyses, reducing the false-positive rate of the screening program by half was the most cost-effective (incrementalcost-effectiveness ratio, ICER=30,110,852 KW/LYS) strategy. When the upper age limit for screening was set at 70 years, itbecame more cost-effective (ICER=39,641,823 KW/LYS) than when no upper age limit was set. The NCSP for breast cancer in Korea seems to be accepted as cost-effective as ICER estimates were around the Gross Domestic Product. However, cost-effectiveness could be further improved by increasing the sensitivity of breast cancer screening and by setting appropriate age limits.

UR - http://www.scopus.com/inward/record.url?scp=84880405562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880405562&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2013.14.3.2059

DO - 10.7314/APJCP.2013.14.3.2059

M3 - Article

VL - 14

SP - 2059

EP - 2065

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 3

ER -